Optimi Health Corp. (OPTH) Stock Score, Valuation & Financial Research
Optimi Health Corp. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 17/100.
Quick answer for OPTH
Optimi Health Corp. currently has a Wall Street Score of 17/100. The stored market price is $5.07. Its financial score is 11/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Optimi Health Corp. does
Based in Princeton, Canada, Optimi Health Corp., established in 2020, is a Canadian entity focused on manufacturing pharmaceutical and nutraceutical products. The company produces and supplies controlled substances, including finalized MDMA and psilocybin drug products, directly to authorized clinics, pharmacies, research trials, and collaborative partners. Their diverse product portfolio extends to MDMA, natural psilocybin, psilocin, other psychedelic compounds, and functional mushrooms, all derived from botanical sources and aimed at the health and wellness market. Optimi Health's operations span cultivation, processing, and distribution of raw mushroom biomass, alongside the creation of mushroom extracts, pharmaceutical drug products, and dietary supplements. These items are available for purchase through the Amazon marketplace, via distributors and brokers, and directly online.
OPTH financial snapshot
- Wall Street Score:
- 17/100
- Current price:
- $5.07
- Market capitalization:
- $16.3M
- Revenue:
- $97K
- Net income:
- $-4.5M
- Free cash flow:
- $-2.0M
- Cash:
- $6.7M
- Total debt:
- $2.6M
- EPS:
- -1.29
- Financial score:
- 11/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is -0.7%.
- Free cash flow is $-2.0M, showing cash burn in the current stored period.
- The balance sheet shows $6.7M of cash versus $2.6M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 11/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research OPTH
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.